Niagen Bioscience (NAGE) Gross Margin (2010 - 2026)
Niagen Bioscience (NAGE) reported Gross Margin of 63.47% for Q1 2026, up 5.0% year-over-year from 60.45% in Q1 2025, and down 1.05% quarter-over-quarter from 64.14% in Q4 2025.
Niagen Bioscience (NAGE) Gross Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 17 years of Gross Margin data on file, last reported at 63.47% in Q1 2026.
- Gross Margin for Q1 2026 came in at 63.47%, up 5.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 64.28% (up 177.0% YoY), and the FY2025 annual result was 64.28%, up 244.0% from the prior year.
- Gross Margin retreated to 63.47% in Q1 2026 per NAGE's latest filing, from 64.14% in the prior quarter.
- Over five years, Gross Margin peaked at 65.0% in Q2 2025 and troughed at 57.23% in Q4 2022.
- A 5-year average of 61.69% and a median of 61.04% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2025: Gross Margin sank 397 bps in 2022, then surged 478 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 57.23% in 2022, then climbed by 7 bps to 61.04% in 2023, then increased by 2 bps to 62.48% in 2024, then rose by 3 bps to 64.14% in 2025, then declined by 1 bps to 63.47% in 2026.
- Business Quant data shows NAGE's Gross Margin at 63.47% in Q1 2026, 64.14% in Q4 2025, and 64.52% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | 63.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.47% |
| Dec 31, 2025 | 64.14% |
| Sep 30, 2025 | 64.52% |
| Jun 30, 2025 | 65.00% |
| Mar 31, 2025 | 63.42% |
| Dec 31, 2024 | 62.48% |
| Sep 30, 2024 | 63.49% |
| Jun 30, 2024 | 60.22% |
| Mar 31, 2024 | 60.74% |
| Dec 31, 2023 | 61.04% |
| Sep 30, 2023 | 61.40% |
| Jun 30, 2023 | 60.80% |
| Mar 31, 2023 | 59.93% |
| Dec 31, 2022 | 57.23% |
| Sep 30, 2022 | 59.82% |
| Jun 30, 2022 | 60.02% |
| Mar 31, 2022 | 61.02% |
| Dec 31, 2021 | 61.20% |
| Sep 30, 2021 | 61.12% |
| Jun 30, 2021 | 61.08% |